实用临床医药杂志2012，Vol.16Issue(17)：116-118,3.
紫杉醇酯质体与紫杉醇治疗晚期非小细胞肺癌临床观察附36例报告
A clinical study on paclitaxel liposome formula and traditional taxel in the treatment of advanced non-small cell lung cancer: A report of 36 cases
蒋志勇 1孟德伍1
作者信息
- 1. 武警江苏省总队医院,江苏扬州,225003
- 折叠
摘要
Abstract
Objective To compare the effects and side effects of paclitaxel liposome formula on advanced non-small cell lung cancer (NSCLC), as a 3-hour non-stop infusion. Methods Fifty four advanced NSCLC patients were randomized into two group. The traditional taxol group (control group, n = 18) was administered the premedications which was used routinely for the prevention of hypersensitivity reactions. The paclitaxel liposome group (study group, n =36) received a 3 -hour non-stop infusion. Results The overall response rate of both groups was 39% . There was no significant difference between the two groups (P≥0. 05). There was no significant difference in roution toxicity between the two groups (P≥0. 05). The toxicity from the mixed solvent of polyethoxylated castor oil and ethanol was significantly lower in the study group than in the control group (P≤0. 05). Conclusion Paclitaxel liposome is effective in the treatment of NSCLC via intravenous infusion. It does not contain cremophor EL. It has less side effects. Even if there are side effects, they are tolerable
关键词
非小细胞肺癌/化学治疗/预处理治疗/紫杉醇酯质体/紫杉醇注射液/不良反应Key words
non-small cell lung cancer/ chemotherapy/ premedication/ paclitaxel liposome/ taxol infusion/ side effects
分类
医药卫生引用本文复制引用
蒋志勇,孟德伍..紫杉醇酯质体与紫杉醇治疗晚期非小细胞肺癌临床观察附36例报告[J].实用临床医药杂志,2012,16(17):116-118,3.
